Table 3.
Patients survived (n = 7) |
Deceased patients (n = 10) |
p value | |
---|---|---|---|
Remdesivir, n | 5 (71%) | 6 (60%) | 0.65 |
Convalescent plasma, n | 3 (43%) | 5 (50%) | 0.79 |
Dexamethasone, n | 3 (43%) | 10 (100%) | 0.004 |
Tocilizumab, n | 6 (86%) | 6 (60%) | 0.28 |
Patients survived (n = 7) |
Deceased patients (n = 10) |
p value | |
---|---|---|---|
Remdesivir, n | 5 (71%) | 6 (60%) | 0.65 |
Convalescent plasma, n | 3 (43%) | 5 (50%) | 0.79 |
Dexamethasone, n | 3 (43%) | 10 (100%) | 0.004 |
Tocilizumab, n | 6 (86%) | 6 (60%) | 0.28 |